Thalidomide
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Thalidomide
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1038
Article Code: 1038c
Date: October 23, 1998
Volume: 40
Pages: 103-104
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1038
Article Code: 1038c
Date: October 23, 1998
Volume: 40
Pages: 103-104
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)